Cosmo Pharmaceuticals N.V.
Stock Forecast, Prediction & Price Target

	Passed			Analyst forecast
Metric	12/31/2021	12/31/2022	12/31/2023	12/31/2025	12/31/2026	12/31/2027
Revenue % change YoY	CHF65.07M N/A	CHF102.08M 56.88%	CHF92.78M -9.11%	Avg: CHF232.80M Low: CHF232.80M High: CHF232.80M avg. 150.92%	Avg: CHF240.66M Low: CHF240.66M High: CHF240.66M avg. 3.37%	Avg: CHF355.79M Low: CHF355.79M High: CHF355.79M avg. 47.83%
Net Income % change YoY	CHF21.67M N/A	CHF17.22M -20.51%	CHF-4.93M -128.63%	Avg: CHF94.19M Low: CHF94.19M High: CHF94.19M avg. 2009.85%	Avg: CHF64.68M Low: CHF64.68M High: CHF64.68M avg. -31.33%	Avg: CHF165.27M Low: CHF165.27M High: CHF165.27M avg. 155.52%
EBITDA % change YoY	CHF40.48M N/A	CHF47.50M 17.34%	CHF19.69M -58.53%	Avg: CHF61.78M Low: CHF61.78M High: CHF61.78M avg. 213.62%	Avg: CHF63.86M Low: CHF63.86M High: CHF63.86M avg. 3.37%	Avg: CHF94.41M Low: CHF94.41M High: CHF94.41M avg. 47.83%
EPS % change YoY	$1.29 N/A	$1.05 -18.60%	-$0.31 -129.52%	Avg: $5.85 Low: $5.85 High: $5.85 avg. 1986.67%	Avg: $4.02 Low: $4.02 High: $4.02 avg. -31.33%	Avg: $10.26 Low: $10.26 High: $10.26 avg. 155.52%
Operating Expenses % change YoY	CHF38.83M N/A	CHF55.27M 42.32%	CHF47.29M -14.43%	Avg: CHF17.10M Low: CHF17.10M High: CHF17.10M avg. -63.82%	Avg: CHF17.68M Low: CHF17.68M High: CHF17.68M avg. 3.37%	Avg: CHF26.14M Low: CHF26.14M High: CHF26.14M avg. 47.83%

FAQ

Wall Street analysts estimate the annual average earnings growth rate of 711.34% in 2025-2027.

We have gathered data from N/A analysts. Their low estimate is 94.19M, average is 94.19M and high is 94.19M.

Wall Street analysts forecast annual average revenue growth of 67.37% in 2025-2027.

We have gathered data from N/A analysts. Their low revenue estimate is CHF232.80M, average is CHF232.80M and high is CHF232.80M.

Wall Street analysts forecast annual average earnings growth of 703.62% in 2025-2027.

We have gathered data from N/A analysts. Their low earnings per share estimate is $5.85, average is $5.85 and high is CHF5.84.